What is bullous pemphigoid?
Bullous pemphigoid is an autoimmune, supepidermal blistering disease.
Who gets bullous pemphigoid?
Bullous pemphigoid often presents in people over 80 years of age, and mostly affects people over 50. It can occur in younger adults, but bullous pemphigoid in infants and children is rare.
- Bullous pemphigoid occurs equally in males and females.
- There are HLA associations indicating genetic predisposition to the disease.
- It is more prevalent in elderly patients with neurological disease, particularly stroke, dementia and Parkinson disease.
- There may be an association with internal malignancy in some patients.
- A drug, an injury, or skin infection can trigger the onset of disease.
What causes bullous pemphigoid?
Bullous pemphigoid is the result of an attack on the basement membrane of the epidermis by IgG +/- IgE immunoglobulins (antibodies) and activated T lymphocytes (white blood cells). The target is the protein BP180 (also called Type XVII collagen), or less frequently BP230 (a plakin). These proteins are within the NC16A domain of collagen XVII. They are associated with the hemidesmosomes, structures that ensure the epidermal keratinocyte cells stick to the dermis to make a waterproof seal.
The binding of the autoantibodies to the proteins and/or release of cytokines from the T cells lead to complement activation, recruitment of neutrophils (acute inflammatory cells) and the release of proteolytic enzymes. These destroy the hemidesmosomes and cause the formation of subepidermal blisters.
The association of neurological disease with the skin disease is thought to relate to the presence of collagen XVII in the central nervous system and in skin hemidesmosomes.
What are the clinical features of bullous pemphigoid?
Bullous pemphigoid causes severe itch and (usually) large, tense bullae (fluid-filled blisters), which rupture forming crusted erosions.
Other variable features include:
- Nonspecific rash for several weeks before blisters appear
- Eczematous areas resembling nummular dermatitis
- Urticaria-like red skin
- Annular (ring-shaped) lesions
- Smaller blisters (vesicles)
- Prurigo nodules
- Clear or cloudy, yellowish or blood stained blister fluid
- Postinflammatory pigmentation
- Milia in healed areas
Bullous pemphigoid may be localized to one area, or widespread on the trunk and proximal limbs.
- Frequently it affects the skin around skin folds.
- Blisters inside the mouth and in genital sites are uncommon.
Some patients have a diagnosis of bullous pemphigoid made despite not having any bullae (non-bullous pemphigoid). This can affect any body site.
Complications of bullous pemphigoid
Bullous pemphigoid can be a serious disease, particularly when widespread or resistant to treatment. Morbidity and mortality result from:
- Bacterial staphylococcal and/or streptococcal skin infection and sepsis
- Complications of treatment
- Underlying and associated diseases
How is bullous pemphigoid diagnosed?
When typical bullae are present, the diagnosis is suspected clinically. In most cases, the diagnosis will be confirmed by a skin biopsy of an early blister. The diagnosis can also be made from non-blistered, inflamed skin.
Pathological examination of bullous pemphigoid shows a split under the epidermis. A dermal neutrophilic infiltrate is usual but not always present. Eosinophils may be prominent.
Direct immunofluorescence staining of a skin biopsy taken adjacent to a blister highlights antibodies along the basement membrane that lies between the epidermis and dermis.
Blood tests include an indirect immunofluorescence test for circulating pemphigoid BP180 antibodies.
Other tests will relate to planning and monitoring treatment.
What is the treatment for bullous pemphigoid?
If the pemphigoid is very widespread, hospital admission may be arranged to dress blisters and erosions.
Medical treatment involves:
- Ultrapotent topical steroids to treat limited disease (eg clobetasol proprionate)
- Moderate potency topical steroids and emollients to relieve itch and dryness
- Systemic steroids
- Steroid-sparing medications
- Antibiotics for secondary bacterial infection
- Pain relief
Most patients with bullous pemphigoid are treated with steroid tablets, usually prednisone. The dose is adjusted until the blisters have stopped appearing, which usually takes several weeks. The dose of prednisone is then slowly reduced over many months or years. As systemic steroids have many undesirable side effects, other medications are added to ensure the lowest possible dose (aiming for 5 to 10mg prednisone daily). These other medications may include:
- Tetracycline antibiotics eg doxycycline
- Intravenous immunoglobulin
People on systemic steroids may also receive additional medicines to alleviate their potential side effects (such as gastritis, hypertension, diabetes and osteoporosis).
Assessment and monitoring
As systemic treatment may be required for bullous pemphigoid for long periods, the extent and severity of the disease should be recorded carefully at baseline and at follow-up appointments. The following aspects may be considered.
- Body sites affected (skin and mucous membranes)
- Type of lesion: transient and non-transient
- Numbers of lesions: blisters, urticarial weals, eczematous plaques,
- Severity of itch
- Observation point: initial phase, active treatment, reducing treatment, maintenance phase on minimal treatment, or complete remission off treatment
- Current treatment
The Bullous Pemphigoid Disease Area Index (BPDAI) has separate scores for skin and mucous membrane activity.
Blood pressure, body weight, DEXA bone scan, and blood tests are required to monitor therapy, as medications used for bullous pemphigoid may have serious side effects in some patients.
How can bullous pemphigoid be prevented?
What is the outlook for bullous pemphigoid?
Treatment is usually needed for several years. In many cases, the pemphigoid eventually completely clears up and the treatment can be stopped. If it recurs, it can be started again.
- Definitions and outcome measures for bullous pemphigoid: Recommendations by an international panel of experts. Journal of the American Academy of Dermatology, Volume 66, Issue 3, March 2012, Pages 479-485. Dedee F. Murrell, Benjamin S. Daniel, Pascal Joly, Luca Borradori, Masayuki Amagai, Takashi Hashimoto, Frédéric Caux, Branka Marinovic, Animesh A. Sinha, Michael Hertl, Philippe Bernard, David Sirois, Giuseppe Cianchini, Janet A. Fairley, Marcel F. Jonkman, Amit G. Pandya, David Rubenstein, Detlef Zillikens, Aimee S. Payne, David Woodley, et al.
- British Association of Dermatologists’ guidelines for the management of bullous pemphigoid 2012. VA Venning, K Taghipour, MF Mohd Mustapa, AS Highet and G Kirtschig, BJD, Vol. 167, No. 6, December 2012 (p1200-1214)
- Chen YJ, Wu CY, Lin MW, Chen TJ, Liao KK, Chen YC, Hwang CY, Chu SY, Chen CC, Lee DD, Chang YT, Wang WJ, Liu HN. Comorbidity profiles among patients with bullous pemphigoid: a nationwide population-based study. Br J Dermatol. 2011 Sep;165(3):593-9. doi: 10.1111/j.1365-2133.2011.10386.x. Epub 2011 Jul 28.
On DermNet NZ:
- Bullous pemphigoid – pathology
- Childhood bullous pemphigoid
- Blistering skin diseases
- Cicatricial pemphigoid
- Epidermolysis bullosa acquisita
- Oral blistering diseases
- International Pemphigus & Pemphigoid Foundation
- Bullous pemphigoid – Medscape Reference
- Pemphigoid – British Association of Dermatologists
- Australasian Blistering Diseases Foundation
See the DermNet NZ bookstore